Adamas reports fourth quarter and full year 2020 financial results

Emeryville, calif.--(business wire)--adamas pharmaceuticals, inc. (nasdaq: adms), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the fourth quarter and full year ended december 31, 2020, and recent corporate highlights. “we are excited with the opportunities ahead of us, including the continued growth of gocovri which is now the first and only medication approved to tr
ADMS Ratings Summary
ADMS Quant Ranking